1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections - Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Clostridioides difficile Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Clostridioides difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridioides difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 9, 9, 34, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 7 molecules, respectively.
Clostridioides difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridioides difficile Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Clostridioides difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Clostridioides difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Clostridioides difficile Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Clostridioides difficile Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Clostridioides difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Overview
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
- Featured News & Press Releases
- Jul 07, 2022: Immuron receives European Patent Notification on drug composition to treat clostridioides difficile associated disease
- Jun 28, 2022: Vedanta unveils state-of-the-art manufacturing facility to provide clinical and commercial supply of oral therapies based on defined bacterial consortia
- Jun 07, 2022: Seres Therapeutics announces confirmatory results from investigational microbiome therapeutic SER-109 ECOSPOR IV open-label study in recurrent C. difficile infection
- May 24, 2022: Ferring presents new analyses of efficacy, safety and microbiome composition data at DDW 2022 for RBX2660 its investigational microbiota-based live biotherapeutic
- May 22, 2022: Seres Therapeutics presents phase III results of SER-109 for recurrent C. Difficile infection at the Digestive Disease Week (DDW) Annual Meeting
- May 19, 2022: Adiso Therapeutics' ADS024 selected for oral presentation at 2022 Digestive Disease Week Annual Meeting
- May 12, 2022: Destiny Pharma: World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration
- May 10, 2022: Seres Therapeutics to present data on investigational microbiome therapeutic SER-109 for recurrent C. difficile infection at the Digestive Disease Week (DDW) Annual Meeting
- Apr 28, 2022: Finch Therapeutics announces removal of FDA clinical hold on CP101 IND
- Apr 21, 2022: Adiso Therapeutics announces completion of enrollment in a phase 1b study of ADS024 for the Prevention of C. difficile Recurrence
- Apr 18, 2022: Lumen Bioscience announces clinical advancement of LMN-201 for C. difficile Infection
- Apr 13, 2022: Vedanta Biosciences publishes phase 1a/1b results for lead program VE303 in Cell Host & Microbe nd highlights planned presentations of phase 2 VE303 results
- Apr 07, 2022: The second part of the phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada
- Mar 01, 2022: Finch Therapeutics provides an update on its phase 3 trial of CP101 in Recurrent C. difficile Infection
- Mar 01, 2022: Phase 3 CLOVER Trial for Pfizer’s investigational Clostridioides Difficile vaccine indicates strong potential effect in reducing duration and severity of disease based on secondary endpoints
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, 2022
- Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acurx Pharmaceuticals Inc
- Adiso Therapeutics Inc
- Affinivax Inc
- Appili Therapeutics Inc
- Ascendo Biotechnology Inc
- Biomica
- Botanix Pharmaceuticals Ltd
- Boulos and Cooper Pharmaceuticals Pty Ltd
- Cambimune Ltd
- Chain Biotechnology Ltd
- Crestone Inc
- CSA Biotechnologies LLC
- Daiichi Sankyo Co Ltd
- Deinove SAS
- Destiny Pharma Plc
- Enterobiotix Ltd
- Facile Therapeutics Inc
- Finch Therapeutics Group Inc
- First Wave BioPharma Inc
- Fzata Inc
- Gateway Pharmaceutical LLC
- GSK plc
- Idorsia Pharmaceutical Ltd
- Immune Biosolutions Inc
- ImmuneBiotech AB
- ImmuniMed Inc
- ImmunoBiology Ltd
- Immuron Ltd
- Inovio Pharmaceuticals Inc
- Integrated BioTherapeutics Inc
- KamTek Inc
- Kowa Co Ltd
- Lumen Bioscience Inc
- Malachite Innovations Inc
- Mapp Biopharmaceutical Inc
- Matrivax Research & Development Corp
- MGB Biopharma Ltd
- Microbiotica Ltd
- Micropharm Ltd
- Mikrobiomik Healthcare Company SL
- MV BioTherapeutics SA
- MyBiotics Pharma Ltd
- Novabiotics Ltd
- NovoBiotic Pharmaceuticals LLC
- Nubiyota LLC
- Oragenics Inc
- Ostrich Pharma USA Inc
- PanTheryx Inc
- Pfizer Inc
- Proxi Biotech IVS
- Pylum Biosciences Inc
- Q2 Pharma Ltd
- QureTech Bio AB
- Rebiotix Inc
- Rebus Holdings Inc
- Recursion Pharmaceuticals Inc
- Sano Chemicals Inc
- Scioto Biosciences Inc
- Secretory IgA Inc
- Seres Therapeutics Inc
- Servatus Ltd
- Summit Therapeutics Inc
- Symbiotic Health Inc
- Synthetic Biologics Inc
- Takeda Pharmaceutical Co Ltd
- TenNor Therapeutics Ltd
- Vedanta Biosciences Inc
- Versatope Therapeutics Inc
- Vifor Pharma Ltd
- XBiotech Inc
- Zhiyi Pharmaceuticals Inc
